Health News Releases

  • Today February 14
February 13, 16:00
Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users
Angelalign Technology Inc. (6699.HK) (“Angel”) said a ruling by the Unified Patent Court of Düsseldorf, Germany that it preliminarily cease its use of certain software functions that automatically upd
February 12, 15:22
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients
February 11, 15:30
Kirin and Immunosens Launch Joint Development of a Self-Testing Service That Uses Urinary IgA to Visualize a Person’s Immune Status
Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service[1]” designed to visualize a person’s immune st
February 11, 15:13
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT based hyaluronic acid injectables ever authorized in J
February 10, 17:30
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54421686&newsitemid=20260210380286&lan=en-US&ancho
February 06, 15:50
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Grou
February 06, 11:40
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncol
InterSystems earns four Best in KLAS awards for 2026
February 06, 10:50
InterSystems Honored with Four 2026 Best in KLAS Awards
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1
February 05, 13:40
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended
Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibilit
February 02, 17:16
Aesthetic Brand Lorient Showcases K-Beauty Excellence at IMCAS World Congress 2026
Lorient, a premium aesthetic brand, announced that it has attracted global attention at the 27th IMCAS World Congress 2026 in Paris, garnering over 15,000 professionals and demonstrating its leadershi
February 02, 15:13
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and l
January 30, 15:34
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course
January 30, 10:50
Organon Completes Divestiture of JADA® System to Laborie
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA®
January 29, 15:52
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54404180&newsitemid=20260128993781&lan=en-US&anc
January 29, 15:24
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing de
January 29, 10:40
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th
January 26, 16:11
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 20
Concept Medical announces first patient enrollment in the STARS DAPT randomized clinical trial evalu
January 25, 13:30
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES
Concept Medical Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.conceptmedical.com%2F&esheet=54401002&newsitemid=20260121338054&lan=en-US&anchor=Concept+Medical+Inc.&index=
January 25, 09:30
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis
Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis
January 23, 09:07
Innovative Research Unveils Potential of Pharmaceutically Processed Mica in Cancer Treatment
A South Korean research team has discovered that pharmaceutically processed mica (PMC), a mineral traditionally used in medicine, may help suppress the growth of non-small cell lung cancer (NSCLC) cel
January 23, 08:30
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the
Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zamb
January 22, 14:30
International Zinc Association Partners With Pharmanova to Save Children in Zambia
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zinc.org%2F&esheet=54398808&newsite
January 22, 09:16
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromo
January 21, 15:20
Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory has achieved College of American Pathologists (CAP) accre
January 21, 13:50
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health
Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization’s work on oral health. The four-year funding commitment will help exp
January 21, 11:50
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas
Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will le
January 21, 10:40
WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54399604&newsitemid=20260119602892&lan=en-US&anc
Jeff Rowe, Syngenta Group CEO
January 19, 17:04
Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access
As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwid
January 18, 13:45
WEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I-IV Trial Delivery Capabilities
WEP Clinical (WEP) (https://www.wepclinical.com/), a full-service contract research organization (CRO), announces the acquisition of Siron Clinical (Siron) (https://sironclinical.com/), a Netherlands-
January 16, 15:10
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Agenus Inc. (https://www.agenusbio.com/) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
January 16, 11:20
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovig
January 15, 15:10
Notice Concerning Change of Representative Executive Officer
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer
January 15, 10:40
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures wit
Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings
January 15, 10:03
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference
Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. “2026 is a monumental year for us, as we enter into a new chapter for
January 14, 17:05
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Agenus Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54393958&newsitemid=20260112699965&lan=en-US&anchor=Agenus+Inc&index=1&md5=e3584ab25f74ab4a2ec4f1
January 14, 16:32
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The compan
January 14, 15:20
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54394840&newsitemid=20260113426214&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
January 13, 14:00
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement desig
January 13, 09:02
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic tr
January 11, 10:45
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administra
January 09, 15:00
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZII
Dr. Anand Tharmaratnam, Novotech CEO and Chairman
January 08, 16:50
Novotech Appoints Anand Tharmaratnam as New CEO
Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. T
January 06, 16:40
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs,
January 06, 09:12
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform
Clonell Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.clonell.com%2F&esheet=54386221&newsitemid=20260105515302&lan=en-US&anchor=Clonell+Therapeutics%2C+Inc.&
January 06, 09:04
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54386774&newsitemid=20260101831438&lan=en-US&anchor=TSE%3A4
January 05, 09:06
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order gov
January 05, 08:54
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2,
Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire)
January 02, 17:00
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 2026
The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare - a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The a
World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospita
December 31, 2025 14:15
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy
Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone p
December 23, 2025 09:19
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of
December 23, 2025 09:07
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Samsung Bioepis Co., Ltd. today announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes ‘NIPRO’, a biosimilar referencing Stelara[1] (ustekinumab), developed by Samsung
December 21, 2025 10:30
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platfo
December 19, 2025 16:50
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation
December 18, 2025 17:09
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54379786&newsitemid=20251218728397&lan=en-US&anchor=TSE%3A4
December 18, 2025 15:00
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On
December 18, 2025 11:45
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deli
December 18, 2025 08:53
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. S
December 17, 2025 15:45
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observ
Early Phase Oncology Infographic
December 16, 2025 15:30
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology - Clinical Research Landscape and CRO
December 14, 2025 14:05
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcomin
Biocytogen Successfully Lists on the STAR Market
December 12, 2025 10:00
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on t
December 11, 2025 17:50
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with th
December 11, 2025 16:35
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating pa
Baszucki Group and Cleveland Clinic Neurological Institute expand impact of landmark brain study to
December 11, 2025 15:40
Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers
Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study (https://my.clevelandclinic.org/departments/neurological/research-innovations/brain-study). Launched
SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia
December 10, 2025 15:35
SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia
SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest p
December 10, 2025 14:10
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innova
December 09, 2025 16:40
IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region
The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (I
December 09, 2025 15:20
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 i
Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart
December 09, 2025 15:00
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results o
December 08, 2025 15:12
Galderma Welcomes Increased Equity Investment From L’Oréal
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
December 05, 2025 17:15
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance o
December 05, 2025 15:40
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU
December 05, 2025 14:15
Parse Biosciences Launches Evercode Whole Blood Fixation
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixati
Deanna Kelly, PharmD, BCPP, Live It, Launch It program lead
December 05, 2025 11:20
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health
Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in
December 05, 2025 11:00
Famenity's Brain Factor-7® Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health
Famenity Co., Ltd. (https://famenity.com/home-en/), a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®)
December 04, 2025 15:09
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive o
November 27, 2025 16:00
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines Ltd (https://beonemedicines.com/). (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and
November 26, 2025 16:20
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (3
November 25, 2025 09:40
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, c
November 23, 2025 11:30
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54361159&newsitemid=20251120303213&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding te
November 21, 2025 14:20
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round wa
The main entrance of K2 MEDITECH headquarters, representing the company’s commitment to innovation a
November 21, 2025 14:07
K2 MEDITECH Sets a New Benchmark in the Global Skin Booster Market
Built on innovative skin-regeneration technology, K2 MEDITECH is rapidly gaining attention in the global beauty and medical aesthetics industries. As a specialized manufacturer of skin boosters, th
November 20, 2025 15:10
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraff
November 20, 2025 15:00
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial e
SPARK Headquarters (SPARK HQ) (Photo: AETOSWire)
November 20, 2025 13:30
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D
In the United Arab Emirates, where cities like Abu Dhabi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fu.ae%2Fen%2Fabout-the-uae%2Fthe-seven-emirates%2FAbu-Dhabi&esheet=54359920&n
November 18, 2025 16:06
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This progra
November 18, 2025 15:10
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pert
November 17, 2025 15:50
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatolog
November 16, 2025 13:40
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune Disease
Third Rock Ventures and Parse Biosciences today announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs) using Parse Biosciences’ GigaLab platform. The
Bernard Tannoury, President of Benta SAS, and Sohail Zaidi, CEO of Ananda Scientific Inc., signing t
November 16, 2025 13:25
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understandin
November 14, 2025 15:10
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play de
November 13, 2025 14:50
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma
The U.S. Food and Drug Administration (FDA) has approved the Promega (https://bit.ly/4nUmP66) OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatelli
November 13, 2025 10:55
InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
InterSystems (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.intersystems.com%2F&esheet=54356186&newsitemid=20251112864064&lan=en-US&anchor=InterSystems&index=1&md5=a79330a679c0
Qorium is successfully producing sustainable real leather
November 12, 2025 16:25
Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation
Qorium, the Dutch biotechnology company pioneering cultivated leather, today announced it has secured a €22 million investment from Invest-NL and LIOF alongside existing investors Brightlands Venture
November 12, 2025 10:40
Prokarium Appoints Ibs Mahmood as Chief Executive Officer
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kri
Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to h
November 11, 2025 16:20
Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms
Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexL
November 10, 2025 15:40
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of
November 10, 2025 10:15
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered
November 09, 2025 09:50
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54353741&newsitemid=20251107689017&lan=en-US&anchor=TSE%3A4
NJ Bio, Inc. now offers translational research services after completing asset purchase and full int
November 07, 2025 11:30
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Res
25 per page50 per page75 per page100 per page